Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

NCT03373435 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Postbariatric Hypoglycemia

Interventions

DRUG: exendin 9-39
OTHER: Placebo

Sponsor

Eiger BioPharmaceuticals